Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 9/20 | 0.72 |
| ▸ | TAS1R2 | Q8TE23 | 9/20 | 0.72 |
| ▸ | TAS1R1 | Q7RTX1 | 8/20 | 0.72 |
| ▸ | PREP | P48147 | 1/20 | 0.47 |
| ▸ | FAP | Q12884 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15962711 | 0.85 | TRPV1 (0.62) | TAS1R3TAS1R2TAS1R1TRPV1TRPM8 | |
| SCHEMBL15962699 | 0.85 | TAS1R3 (0.74) | TAS1R3TAS1R2TAS1R1CHRM1 | |
| SCHEMBL15962707 | 0.85 | TAS1R3 (0.74) | TAS1R3TAS1R2TAS1R1CHRM1 | |
| SCHEMBL704087 | 0.84 | TAS1R3 (1.00) | TAS1R3TAS1R2TAS1R1 | |
| SCHEMBL15955764 | 0.84 | TAS1R3 (1.00) | TAS1R3TAS1R2TAS1R1 | |
| SCHEMBL15956230 | 0.84 | TAS1R3 (1.00) | TAS1R3TAS1R2TAS1R1 | |
| SCHEMBL15962706 | 0.84 | TAS1R3 (1.00) | TAS1R3TAS1R2TAS1R1 | |
| SCHEMBL15955931 | 0.84 | TAS1R3 (1.00) | TAS1R3TAS1R2TAS1R1 | |
| SCHEMBL15956199 | 0.84 | TAS1R3 (0.73) | TAS1R3TAS1R2TAS1R1PREPFAP | |
| SCHEMBL15956105 | 0.84 | TAS1R3 (1.00) | TAS1R3TAS1R2TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137376-A1 | AMIDE COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100137376-A1 | AMIDE COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100137376-A1 | AMIDE COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| EP-2174931-A1 | AMIDE COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME | Sumitomo Chemical Company, Limited (JP) | 2010-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137376-A1 | AMIDE COMPOUND AND METHOD FOR CONTROLLING PLANT DISEASE USING THE SAME | NAAA, NAT1, SAT1 | TAS1R3 4053/4885TAS1R2 3382/4885TAS1R1 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.